Our mission is to bring hope and life-changing therapies to patients and their families affected by rare diseases, and our primary focus is Duchenne muscular dystrophy.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $52.8M
Founded date: 2008
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.03.2015 | - | $20.4M | - |
| 15.11.2013 | Series B | $32.4M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.04.2021 | CATABASIS PHARMACEUTICALS, INC. Catabasis Pharmaceuticals : 2020 Annual Report | 2020 ANNUAL REPORT Dear Shareholders, While the past year has been a period of change for Catabasis, our commitment to bringing hope with life- changing therapies to patients and families remains the same. We recently acquired Quellis Biosc... |
| 01.02.2021 | Catabasis Pharmaceuticals Acquires Quellis Biosciences | Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases. The private placement is expected to ... |
| 04.08.2020 | Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis | BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non... |
| 31.01.2017 | Catabasis shares are shredded after lead drug flops in PhII Duchenne MD study | Catabasis’ lead drug just flopped in a Phase II study for Duchenne muscular dystrophy, eviscerating its stock after yet another clinical setback raises questions about its competence and direction. The drug, CAT-1004 (e... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 31.03.2015 | Catabasis raising $20.4M; modulates multiple disease pathways for Duchenne muscular dystrophy, ALS | The MIT Technology Review wrote up a nice explainer of Catabasis’ technology two years ago: Catabasis has found a way around the challenge of identifying a single active molecule that can hit multiple pathways effectively: using a chemical ... |
| 01.05.2014 | Morgenthaler, ATV vets team up for new $172M early-stage life science venture capital fund | Carusi said in a statement that a lively IPO market, improvements at the FDA and interest from large corporate players to invest in and acquire life science companies has created a lot of promise in the sector, making it appealing for inves... |
| 15.11.2013 | Catabasis Closes $32.4M Series B | CAMBRIDGE, MA, Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. >> Click here for more funding data on Catabasis >> To export... |
| 15.11.2013 | Catabasis Pharmaceuticals Completes $32.4M Series B Financing | Catabasis Pharmaceuticals, Inc., a Cambridge, Mass.-based clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases, completed a $32.4m Series B financing. The rou... |
| 06.02.2013 | Catabasis raises $9M for PhII-ready drug development program | Catabasis Pharmaceuticals has gone back to the well to raise close to $9 million, according to documents filed with the Securities and Exchange Commission. Cambridge, MA-based Catabasis scored an additional $8 million for its Series A back ... |
Show more